ArticleBMC cancer2026
A radiomics and machine learning-based method for dynamic assessment of tumor burden after neoadjuvant therapy in esophageal cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConventional response evaluation criteria primarily rely on tumor size reduction to assess the efficacy of neoadjuvant therapy (NAT) in esophageal cancer. However, these morphological assessments often fail to capture the underlying biological changes, as some patients achieve substantial pathological response without marked tumor shrinkage. To address this limitation, we introduced the concept of tumor burden (TB), integrating both tumor volume (TV) and tumor regression grade (TRG), and proposed four novel parameters—TV change ratio (TVCR), pre-NAT mean cross-sectional area (Pre-NT MCSA), post-NAT MCSA (Post-NT MCSA), and post-NAT mean cross-sectional TB (Post-NT MCTB)—to better quantify residual disease.
methodsWe conducted a retrospective study of 204 esophageal cancer patients who underwent NAT followed by minimally invasive esophagectomy between September 2019 and September 2024. The relationships between the four novel parameters and resection status were evaluated. Subsequently, a radiomics-based random forest model was developed to predict post-NAT TB (Post-NT TB) from pre- and post-NAT CT images.
resultsAmong the four parameters, only Post-NT MCTB showed a significant association with resection status (p < 0.01), confirming its clinical relevance in reflecting residual TB. The radiomics-based model demonstrated robust predictive performance, achieving a coefficient of determination (R²) of 0.85 in the test set.
conclusionsPost-NT MCTB serves as a clinically relevant indicator of residual TB after NAT, surpassing traditional volume-based assessment. This radiomics-based framework enables dynamic and quantitative evaluation that may assist preoperative planning in esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.